Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Is Fabre-Kramer’s Gepirone Antidepressant Rising From The Dead After 8 Years?

This article was originally published in The Pink Sheet Daily

Executive Summary

Nothing has been heard about the major depressive disorder treatment since FDA issued a third “not approvable” letter in 2007; advisory committee to discuss NDA in December.

Advertisement

Related Content

Do Negative Trials Count More Than Successful Ones?
Recent And Upcoming FDA Advisory Committee Meetings
Recent And Upcoming FDA Advisory Committee Meetings
Recent And Upcoming FDA Advisory Committee Meetings
Recent And Upcoming FDA Advisory Committee Meetings
Recent And Upcoming FDA Advisory Committee Meetings
Recent And Upcoming FDA Advisory Committee Meetings
Recent And Upcoming FDA Advisory Committee Meetings
Third Strike For Gepirone ER: Fabre-Kramer/GSK Antidepressant “Not Approvable” Again
Fabre-Kramer/GSK Submit Gepirone ER For Major Depressive Disorder

Topics

Related Companies

Related Deals

Advertisement
UsernamePublicRestriction

Register

PS078988

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

All set! This Question has been sent to my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel